CBIA News Alert Canopus Biopharma In (CBIA) 0.1000 09/19/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Canopus Biopharma In (CBIA) 0.1000 $CBIA

Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China
PR Newswire - Tue Jul 01, 9:00AM CDT
Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM) was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts. A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir(TM) Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir(TM).

Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Latest Rhinovirus Infection Pipeline Review
M2 - Tue Jan 28, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5q9nz/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H2 2013" report to their offering. 'Rhinovirus Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection. Scope - A snapshot of the global therapeutic scenario for Rhinovirus Infection. - A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhinovirus Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Canopus BioPharma Incorporated - Cocrystal Discovery, Inc. - Sealife PHARMA GMBH - Polyrizon Ltd. Drug Profiles - SLP-0904 - OBR-5-340 - CB-1600 - Drug For Rhinovirus Infection - SLP-1001 - Human Rhinovirus Program - PL-402 - Human Rhinovirus Inhibitors - Rhinovirus Program - KR-22809 - Amiloride Derivatives For more information visit http://www.researchandmarkets.com/research/m5q9nz/rhinovirus

Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.

Oral Mucositis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wgg6sd/oral_mucositis) has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2013" report to their offering. 'Oral Mucositis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Oral Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Mucositis. Scope - A snapshot of the global therapeutic scenario for Oral Mucositis. - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Oral Mucositis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Oral Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Daewoong Pharmaceutical Co., Ltd. Soligenix, Inc. BioAlliance Pharma SA Sucampo Pharmaceuticals, Inc. ActogeniX NV Alder Biopharmaceuticals Inc. Promedior, Inc. ProCertus BioPharm Inc. GliaMed, Inc. Avaxia Biologics, Inc. Canopus BioPharma Incorporated Nephrx Corporation Tosk, Inc. Laila Pharmaceuticals Pvt. Ltd. Applied Protein Sciences, LLC For more information visit http://www.researchandmarkets.com/research/wg..._mucositis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Periodontal Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Those in the Dental Field
M2 - Wed Sep 04, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp3kl2/periodontal) has announced the addition of the "Periodontal Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Periodontal Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. Periodontal Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aphios Corporation - Biomedical Development Corporation - CSL Limited - Canopus BioPharma Incorporated - Ensoltek Co., Ltd. - Kaken Pharmaceutical Co.,Ltd. - NeoStem, Inc. - Onepharm Research and Development GmbH - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/sp...eriodontal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Periodontitis - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2qfrh/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2013" report to their offering. 'Periodontitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis prod

Mucositis - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z2zdt/mucositis) has announced the addition of the "Mucositis - Pipeline Review, H1 2013" report to their offering. "Mucositis - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identify

H3N2 Infection - Pipeline Review, H1 2013 Featuring 7 Key Companies and 9 Drug Profiles
M2 - Mon Apr 29, 4:21AM CDT
Research and Markets has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2013" report to their offering. 'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H3N2 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H3N2 Infection. Scope - A snapshot of the global therapeutic scenario for H3N2 Infection. - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the H3N2 Infection pipeline on the basis of route of

Canopus BioPharma Incorporated - Product Pipeline Review - 2012
M2 - Mon Feb 18, 3:33AM CST
Summary




Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 454

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 77

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading